Recombinant bacterial vaccines

Current Opinion in Immunology

Volumn 24, Issue 3, 2012, Pages 337-342

  Unnikrishnan, Meera ^a   Rappuoli, Rino ^a   Serruto, Davide ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; BACTERIAL VACCINE; BACTERIUM ANTIBODY; BCG VACCINE; GLYCOCONJUGATE; LIVE VACCINE; MENINGOCOCCUS VACCINE; PERTUSSIS VACCINE; RECOMBINANT PROTEIN; RECOMBINANT VACCINE;

ANTIBODY RESPONSE; BACILLUS ANTHRACIS; BACTERIAL OUTER MEMBRANE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; ESCHERICHIA COLI; GENETIC MANIPULATION; GENOMICS; GROUP B STREPTOCOCCAL INFECTION; HUMAN; IMMUNOGENICITY; LACTIC ACID BACTERIUM; LUNG TUBERCULOSIS; MEMBRANE VESICLE; MYCOBACTERIUM TUBERCULOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; PROTEIN STRUCTURE; RECOMBINANT DNA TECHNOLOGY; REVIEW; SALMONELLA; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; BACTERIAL INFECTIONS; BACTERIAL VACCINES; HUMANS; PROTEIN SUBUNITS; VACCINES, SYNTHETIC;

EID: 84862674433     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2012.03.013     Document Type: Review

References (51)

1. Plotkin S.A., Plotkin S.L. The development of vaccines: how the past led to the future. Nat Rev Microbiol 2011, 9:889-893.
2. Rappuoli R., Black S., Lambert P.H. Vaccine discovery and translation of new vaccine technology. Lancet 2011, 378:360-368.
3. Andre F.E. Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine. Vaccine 1990, 8(Suppl.):S74-S78. discussion S79-80.
4. Pizza M., Covacci A., Bartoloni A., Perugini M., Nencioni L., De Magistris M.T., Villa L., Nucci D., Manetti R., Bugnoli M., et al. Mutants of pertussis toxin suitable for vaccine development. Science 1989, 246:497-500.
5. Campbell J.D., Clement K.H., Wasserman S.S., Donegan S., Chrisley L., Kotloff K.L. Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults. Hum Vaccin 2007, 3:205-211.
6. Brown B.K., Cox J., Gillis A., VanCott T.C., Marovich M., Milazzo M., Antonille T.S., Wieczorek L., McKee K.T., Metcalfe K., et al. Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adults. PLoS ONE 2010, 5:e13849.
7. Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 2001, 19:2688-2691.
8. Pizza M., Scarlato V., Masignani V., Giuliani M.M., Arico B., Comanducci M., Jennings G.T., Baldi L., Bartolini E., Capecchi B., et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000, 287:1816-1820.
9. Giuliani M.M., Adu-Bobie J., Comanducci M., Arico B., Savino S., Santini L., Brunelli B., Bambini S., Biolchi A., Capecchi B., et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 2006, 103:10834-10839.
10. Findlow J., Borrow R., Snape M.D., Dawson T., Holland A., John T.M., Evans A., Telford K.L., Ypma E., Toneatto D., et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010, 51:1127-1137.
11. Kimura A., Toneatto D., Kleinschmidt A., Wang H., Dull P. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin Vaccine Immunol 2011, 18:483-486.
12. Santolaya M.E., O'Ryan M.L., Valenzuela M.T., Prado V., Vergara R., Munoz A., Toneatto D., Grana G., Wang H., Clemens R., et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012, 379:617-624.
13. Snape M.D., Klinger C.L., Daniels E.D., John T.M., Layton H., Rollinson L., Pestridge S., Dymond S., Galiza E., Tansey S., et al. Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial. Pediatr Infect Dis J 2010, 29:e80-e90.
14. Maione D., Margarit I., Rinaudo C.D., Masignani V., Mora M., Scarselli M., Tettelin H., Brettoni C., Iacobini E.T., Rosini R., et al. Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science 2005, 309:148-150.
15. Lauer P., Rinaudo C.D., Soriani M., Margarit I., Maione D., Rosini R., Taddei A.R., Mora M., Rappuoli R., Grandi G., et al. Genome analysis reveals pili in Group B Streptococcus. Science 2005, 309:105.
16. Moriel D.G., Bertoldi I., Spagnuolo A., Marchi S., Rosini R., Nesta B., Pastorello I., Corea V.A., Torricelli G., Cartocci E., et al. Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli. Proc Natl Acad Sci USA 2010, 107:9072-9077.
17. Serruto D., Serino L., Masignani V., Pizza M. Genome-based approaches to develop vaccines against bacterial pathogens. Vaccine 2009, 27:3245-3250.
18. Harfouche C., Filippini S., Gianfaldoni C., Ruggiero P., Moschioni M., Maccari S., Pancotto L., Arcidiacono L., Galletti B., Censini S., et al. RrgB321, a fusion protein of the three variants of the pneumococcal pilus backbone RrgB, is protective in vivo and elicits opsonic antibodies. Infect Immun 2012, 80:451-460.
19. Madico G., Ngampasutadol J., Gulati S., Vogel U., Rice P.A., Ram S. Factor H binding and function in sialylated pathogenic neisseriae is influenced by gonococcal, but not meningococcal, porin. J Immunol 2007, 178:4489-4497.
20. McShane H. Tuberculosis vaccines: beyond bacille Calmette-Guerin. Philos Trans R Soc Lond B Biol Sci 2011, 366:2782-2789.
21. Pesciaroli M., Aloisio F., Ammendola S., Pistoia C., Petrucci P., Tarantino M., Francia M., Battistoni A., Pasquali P. An attenuated Salmonella enterica serovar Typhimurium strain lacking the ZnuABC transporter induces protection in a mouse intestinal model of Salmonella infection. Vaccine 2011, 29:1783-1790.
22. Sun R., Skeiky Y.A., Izzo A., Dheenadhayalan V., Imam Z., Penn E., Stagliano K., Haddock S., Mueller S., Fulkerson J., et al. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Vaccine 2009, 27:4412-4423.
23. Harro C., Sack D., Bourgeois A.L., Walker R., DeNearing B., Feller A., Chakraborty S., Buchwaldt C., Darsley M.J. A combination vaccine consisting of three live attenuated enterotoxigenic Escherichia coli strains expressing a range of colonization factors and heat-labile toxin subunit B is well tolerated and immunogenic in a placebo-controlled double-blind phase I trial in healthy adults. Clin Vaccine Immunol 2011, 18:2118-2127.
24. Colditz G.A., Brewer T.F., Berkey C.S., Wilson M.E., Burdick E., Fineberg H.V., Mosteller F. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994, 271:698-702.
25. Rodrigues L.C., Diwan V.K., Wheeler J.G. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 1993, 22:1154-1158.
26. Horwitz M.A., Harth G. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect Immun 2003, 71:1672-1679.
27. Hoft D.F., Blazevic A., Abate G., Hanekom W.A., Kaplan G., Soler J.H., Weichold F., Geiter L., Sadoff J.C., Horwitz M.A. A new recombinant bacille Calmette-Guerin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J Infect Dis 2008, 198:1491-1501.
28. Grode L., Seiler P., Baumann S., Hess J., Brinkmann V., Nasser Eddine A., Mann P., Goosmann C., Bandermann S., Smith D., et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 2005, 115:2472-2479.
29. Desel C., Dorhoi A., Bandermann S., Grode L., Eisele B., Kaufmann S.H. Recombinant BCG DeltaureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses. J Infect Dis 2011, 204:1573-1584.
30. Hinchey J., Jeon B.Y., Alley H., Chen B., Goldberg M., Derrick S., Morris S., Jacobs W.R., Porcelli S.A., Lee S. Lysine auxotrophy combined with deletion of the SecA2 gene results in a safe and highly immunogenic candidate live attenuated vaccine for tuberculosis. PLoS ONE 2011, 6:e15857.
31. Wells J.M., Mercenier A. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol 2008, 6:349-362.
32. Oliveira M.L., Areas A.P., Campos I.B., Monedero V., Perez-Martinez G., Miyaji E.N., Leite L.C., Aires K.A., Lee Ho P. Induction of systemic and mucosal immune response and decrease in Streptococcus pneumoniae colonization by nasal inoculation of mice with recombinant lactic acid bacteria expressing pneumococcal surface antigen A. Microbes Infect 2006, 8:1016-1024.
33. Robinson K., Chamberlain L.M., Schofield K.M., Wells J.M., Le Page R.W. Oral vaccination of mice against tetanus with recombinant Lactococcus lactis. Nat Biotechnol 1997, 15:653-657.
34. Buccato S., Maione D., Rinaudo C.D., Volpini G., Taddei A.R., Rosini R., Telford J.L., Grandi G., Margarit I. Use of Lactococcus lactis expressing pili from group B Streptococcus as a broad-coverage vaccine against streptococcal disease. J Infect Dis 2006, 194:331-340.
35. Hegazy W.A., Hensel M. Salmonella enterica as a vaccine carrier. Future Microbiol 2012, 7:111-127.
36. Hohmann E.L., Oletta C.A., Miller S.I. Evaluation of a phoP/phoQ-deleted, aroA-deleted live oral Salmonella typhi vaccine strain in human volunteers. Vaccine 1996, 14:19-24.
37. Baillie L.W., Rodriguez A.L., Moore S., Atkins H.S., Feng C., Nataro J.P., Pasetti M.F. Towards a human oral vaccine for anthrax: the utility of a Salmonella typhi Ty21a-based prime-boost immunization strategy. Vaccine 2008, 26:6083-6091.
38. Gomez-Duarte O.G., Lucas B., Yan Z.X., Panthel K., Haas R., Meyer T.F. Protection of mice against gastric colonization by Helicobacter pylori by single oral dose immunization with attenuated Salmonella typhimurium producing urease subunits A and B. Vaccine 1998, 16:460-471.
39. Darji A., zur Lage S., Garbe A.I., Chakraborty T., Weiss S. Oral delivery of DNA vaccines using attenuated Salmonella typhimurium as carrier. FEMS Immunol Med Microbiol 2000, 27:341-349.
40. Xiong G., Husseiny M.I., Song L., Erdreich-Epstein A., Shackleford G.M., Seeger R.C., Jackel D., Hensel M., Metelitsa L.S. Novel cancer vaccine based on genes of Salmonella pathogenicity island 2. Int J Cancer 2010, 126:2622-2634.
41. Singh R., Wallecha A. Cancer immunotherapy using recombinant Listeria monocytogenes: transition from bench to clinic. Hum Vaccin 2011, 7:497-505.
42. Keiser P.B., Biggs-Cicatelli S., Moran E.E., Schmiel D.H., Pinto V.B., Burden R.E., Miller L.B., Moon J.E., Bowden R.A., Cummings J.F., et al. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine 2011, 29:1413-1420.
43. Koeberling O., Seubert A., Santos G., Colaprico A., Ugozzoli M., Donnelly J., Granoff D.M. Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys. Vaccine 2011, 29:4728-4734.
44. Pinto V.B., Moran E.E., Cruz F., Wang X.M., Fridman A., Zollinger W.D., Przysiecki C.T., Burden R. An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups. Vaccine 2011, 29:7752-7758.
45. Collins B.S. Gram-negative outer membrane vesicles in vaccine development. Discov Med 2011, 12:7-15.
46. Schroeder J., Aebischer T. Recombinant outer membrane vesicles to augment antigen-specific live vaccine responses. Vaccine 2009, 27:6748-6754.
47. Nuccitelli A., Cozzi R., Gourlay L.J., Donnarumma D., Necchi F., Norais N., Telford J.L., Rappuoli R., Bolognesi M., Maione D., et al. Structure-based approach to rationally design a chimeric protein for an effective vaccine against Group B Streptococcus infections. Proc Natl Acad Sci USA 2011, 108:10278-10283.
48. Scarselli M., Arico B., Brunelli B., Savino S., Di Marcello F., Palumbo E., Veggi D., Ciucchi L., Cartocci E., Bottomley M.J., et al. Rational design of a meningococcal antigen inducing broad protective immunity. Sci Transl Med 2011, 3:91ra62.
49. Feldman M.F., Wacker M., Hernandez M., Hitchen P.G., Marolda C.L., Kowarik M., Morris H.R., Dell A., Valvano M.A., Aebi M. Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli. Proc Natl Acad Sci USA 2005, 102:3016-3021.
50. Fisher A.C., Haitjema C.H., Guarino C., Celik E., Endicott C.E., Reading C.A., Merritt J.H., Ptak A.C., Zhang S., DeLisa M.P. Production of secretory and extracellular N-linked glycoproteins in Escherichia coli. Appl Environ Microbiol 2011, 77:871-881.
51. Ihssen J., Kowarik M., Dilettoso S., Tanner C., Wacker M., Thony-Meyer L. Production of glycoprotein vaccines in Escherichia coli. Microb Cell Fact 2010, 9:61.